Pfizer COVID-19 vaccine trial

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:clinical_trial
gptkbp:adverseEventsMonitored	fever fatigue headache injection site pain serious adverse events
gptkbp:ageRange	16 years and older
gptkbp:clinicalTrialPhase	gptkb:NCT04368728 multinational placebo-controlled randomized observer-blinded
gptkbp:conductedBy	gptkb:Pfizer gptkb:BioNTech
gptkbp:doseInterval	21 days
gptkbp:effect	about 95%
gptkbp:endPoint	prevention of symptomatic COVID-19
https://www.w3.org/2000/01/rdf-schema#label	Pfizer COVID-19 vaccine trial
gptkbp:location	gptkb:Argentina gptkb:Brazil gptkb:Germany gptkb:South_Africa gptkb:Turkey gptkb:United_States
gptkbp:numberOfDoses	2
gptkbp:participants	over 43,000
gptkbp:period	Phase 1 Phase 2 Phase 3
gptkbp:publicationDate	December 2020
gptkbp:publishedIn	gptkb:The_New_England_Journal_of_Medicine
gptkbp:regulatorySubmission	gptkb:FDA gptkb:EMA gptkb:MHRA
gptkbp:resultedIn	gptkb:emergency_use_authorization full approval (later)
gptkbp:safetyMonitoring	gptkb:Data_Monitoring_Committee
gptkbp:sponsor	gptkb:Pfizer gptkb:BioNTech
gptkbp:startDate	April 2020
gptkbp:studiedVaccine	gptkb:BNT162b2
gptkbp:trialPopulation	older adults diverse ethnic backgrounds healthy adults people with comorbidities
gptkbp:vaccineType	vaccine
gptkbp:bfsParent	gptkb:Brooke_Jackson
gptkbp:bfsLayer	6